Market revenue in 2023 | USD 2,698.7 million |
Market revenue in 2030 | USD 4,798.5 million |
Growth rate | 8.6% (CAGR from 2023 to 2030) |
Largest segment | Glp-1 receptor agonists |
Fastest growing segment | GLP-1 Receptor Agonists |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Others Drug Class, Insulin |
Key market players worldwide | AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Co Ltd, Eli Lilly and Co, Boehringer Ingelheim, Bristol-Myers Squibb Co, Pfizer Inc, Johnson & Johnson, Merck & Co Inc, Novartis AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antidiabetics market will help companies and investors design strategic landscapes.
Glp-1 receptor agonists was the largest segment with a revenue share of 35.49% in 2023. Horizon Databook has segmented the Japan antidiabetics market based on glp-1 receptor agonists, dpp- 4 inhibitors, sglt2 inhibitors, others drug class, insulin covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan antidiabetics market, including forecasts for subscribers. This country databook contains high-level insights into Japan antidiabetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account